Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.

"Declaration of personal interests : SD has received lecture fees from and served as a consultant for AbbVie, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, TiGenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, and Boehringer Ingelheim. KS has nothing to declare. JVZ has received financial support for research from PPD, Roche, and AbbVie; and served on advisory boards for Janssen and Ferring. SA, DL, and JR are employees of and hold Takeda stock or stock options. SV has received financial support for research from AbbVie, Takeda, Pfizer, Johnson & Johnson; received lecture fees from Merck Sharp & Dohme Corp., AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, Genentech/Roche, and Tillotts; and served as a consultant for Merck Sharp & Dohme Corp., AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, Johnson & Johnson, Genentech/Roche, Celgene, Mundipharma, Celltrion, Second Genome, Prometheus, Gilead, Galapagos, ProDigest, Abivax, GSK, and Tillotts."

"Funding information"